For more information or confidential assistance
800-306-3180
se habla español

MDL Centralization Sought for Valsartan Litigation

FDA
A motion was recently filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) that seeks to consolidate federal complaints filed with regard to valsartan, a generic hypertension drug. The motion was filed late in October 2018 by Robert Kruk on behalf of himself and other plaintiffs with pending valsartan lawsuits. Kruk... Read more »

Early Trials Selected for Growing Androgel Lawsuits

Eight Androgel lawsuits have been selected out of around 5,500 cases currently pending to serve as bellwether trials in the coordinated litigation. The bellwether trials are carefully selected to provide insight into how juries might respond to evidence and testimony in future trials. These early trials also can serve as... Read more »

New Study Highlights Nexium Dangers

Recent large scale epidemiological and retrospective studies have demonstrated links between the use of proton pump inhibitors (PPIs) and an increased risk of renal failure, myocardial infarction and dementia. On top of this, medical experts say that up to 70 percent of patients that take PPIs for treatment of heartburn... Read more »

Government Office Expresses Concern With FDA Drug Oversight

The federal Food and Drug Administration (FDA) is tasked with the tremendous responsibility of keeping American consumers safe from dangerous drugs and medical devices. Accordingly, the agency has not only implemented strict pre-market testing and screening measures for new products, but it is required to monitor the products after their... Read more »

New Report Warns of 21st Century Cures Act Shortfalls

drugreporter.com
In December 2015, non-profit group Public Citizen published a report highlighting a provision in the proposed 21st Century Cures Act that could cost taxpayers $12 billion — and that’s just one of the expenses. The report — written by Sammy Almashat and Sarah Sorscher of Public Citizen’s Health Research Group... Read more »